Back to top

Myriad Genetics Inc: (NSDQ: MYGN)

(U.S: NSDQ) As of Jul 29, 2014 03:59 PM ET

 Add to portfolio

 ZacksTrade Now

$37.05 USD

37.05

+0.94 (2.60%)

Volume: 642,724

Zacks Rank : 3-Hold [?]     3    

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1 Strong Buy 26.65%
2 Buy 18.84%
3 Hold 10.45%
4 Sell 4.76%
5 Strong Sell 2.56%
S&P 500 10.28%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The way to access to the Zacks Rank

Company Summary

Myriad Genetics, Inc. uses gene-based medicine to develop therapeutic and molecular diagnostic products. They employ a variety of proprietary proteomic technologies to discover disease genes and to understand the role these genes and their related proteins play in the onset and progression of disease. They have integrated these technologies using bioinformatics and robotics systems to conduct their research efforts on a high-throughput basis. This has enabled them to identify numerous proteins as targets for new drugs and molecular diagnostic tests.

General Information

MYRIAD GENETICS

320 WAKARA WAY

SALT LAKE CITY, UT 84108

Phone: 801-584-3640

Fax: 801-584-3640

Web: http://www.myriad.com

Email: sgleason@myriad.com

Industry MED-BIOMED/GENE
Sector Medical
Fiscal Year End June
Last Reported Quarter 6/30/2014
Next EPS Date 8/12/2014

EPS Information

Current Quarter EPS Consensus Estimate 0.46
Current Year EPS Consensus Estimate 2.40
Estimated Long-Term EPS Growth Rate 14.90
Next EPS Report Date 8/12/2014

Price and Volume Information

Zacks Rank
Yesterday's Close 36.11
52 Week High 42.50
52 Week Low 20.02
Beta 0.78
20 Day Moving Average 672,259.25
Target Price Consensus 36.60

MYGN

% Price Change
4 Week -7.22
12 Week -11.84
YTD 76.45
% Price Change Relative to S&P 500
4 Week -8.10
12 Week -16.04
YTD 64.86
Share Information
Shares Outstanding (millions) 74.82
Market Capitalization (millions) 2,701.90
Short Ratio 31.54
Last Split Date 3/26/2009
Dividend Information
Dividend Yield 0.00%
Annual Dividend $0.00
Payout Ratio 0.00
Change in Payout Ratio NA
Last Dividend Payout / Amount NA / $0.00

Fundamental Ratios

P/E
P/E (F1) 17.51
Trailing 12 Months 14.62
PEG Ratio 1.18
EPS Growth
vs. Previous Year 30.43%
vs. Previous Quarter -9.09%
   
Sales Growth
vs. Previous Year 16.91%
vs. Previous Quarter -10.36%
   
Price Ratios
Price/Book 3.65
Price/Cash Flow 18.44
Price / Sales 3.54
ROE
6/30/14 NA
3/31/14 27.78
12/31/13 27.22
ROA
6/30/14 NA
3/31/14 24.78
12/31/13 24.46
Current Ratio
6/30/14 NA
3/31/14 4.69
12/31/13 6.74
Quick Ratio
6/30/14 NA
3/31/14 4.42
12/31/13 6.74
Operating Margin
6/30/14 NA
3/31/14 25.63
12/31/13 25.48
Net Margin
6/30/14 NA
3/31/14 24.45
12/31/13 25.48
Pre-Tax Margin
6/30/14 NA
3/31/14 38.31
12/31/13 39.94
Book Value
6/30/14 NA
3/31/14 9.90
12/31/13 9.04
Inventory Turnover
6/30/14 NA
3/31/14 16.78
12/31/13 31.00
Debt-to-Equity
6/30/14 NA
3/31/14 0.00
12/31/13 0.00
Debt to Capital
6/30/14 NA
3/31/14 0.00
12/31/13 0.00